F50067 is a humanized monoclonal IgG1 anti-CXCR4 antibody and exerts antitumor effects via reducing the interaction of MM cells with the BM microenvironment and inducing antibody-dependent cellular cytotoxicity and compliment-dependent cytotoxicity. Here, CXCR4 is linked to Miyoshi myopathy.